119 related articles for article (PubMed ID: 24394199)
1. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Wiese MD; Alotaibi N; O'Doherty C; Sorich MJ; Suppiah V; Cleland LG; Proudman SM
Pharmacogenomics J; 2014 Aug; 14(4):350-5. PubMed ID: 24394199
[TBL] [Abstract][Full Text] [Related]
2. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
4. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.
Zhang LL; Yang S; Wei W; Zhang XJ
Pharmacogenet Genomics; 2014 Nov; 24(11):531-8. PubMed ID: 25144752
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
Soejima M; Kawaguchi Y; Hara M; Kamatani N
J Rheumatol; 2008 Apr; 35(4):724. PubMed ID: 18398952
[No Abstract] [Full Text] [Related]
7. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene.
Tanaka E; Taniguchi A; Urano W; Nakajima H; Matsuda Y; Kitamura Y; Saito M; Yamanaka H; Saito T; Kamatani N
J Rheumatol; 2002 Dec; 29(12):2492-9. PubMed ID: 12465141
[TBL] [Abstract][Full Text] [Related]
8. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
Wadelius M; Stjernberg E; Wiholm BE; Rane A
Pharmacogenetics; 2000 Feb; 10(1):35-41. PubMed ID: 10739170
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.
Soukup T; Dosedel M; Nekvindova J; Toms J; Vlcek J; Pavek P
Clin Exp Rheumatol; 2015; 33(3):426-32. PubMed ID: 25664505
[TBL] [Abstract][Full Text] [Related]
12. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
Taniguchi A; Urano W; Tanaka E; Akama H; Yamanaka H; Kamatani N
Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
15. Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.
Xiao W; Guo JP; Li C; Ye H; Wei W; Zou Y; Dai L; Li Z; Zhang M; Li X; Cai X; Zhao J; Wang Y; Tao Y; Liu D; Li Y; Wu M; Sun E; Wu L; Luo L; Mu R; Li Z
Pharmacogenomics; 2018 Apr; 19(5):383-392. PubMed ID: 29517409
[TBL] [Abstract][Full Text] [Related]
16. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.
Choy EH; Scott DL; Kingsley GH; Williams P; Wojtulewski J; Papasavvas G; Henderson E; Macfarlane D; Erhardt C; Young A; Plant MJ; Panayi GS
Clin Exp Rheumatol; 2002; 20(3):351-8. PubMed ID: 12102471
[TBL] [Abstract][Full Text] [Related]
17. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
Proudman SM; James MJ; Spargo LD; Metcalf RG; Sullivan TR; Rischmueller M; Flabouris K; Wechalekar MD; Lee AT; Cleland LG
Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
[TBL] [Abstract][Full Text] [Related]
18. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
[TBL] [Abstract][Full Text] [Related]
19. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
Jenko B; Lusa L; Tomsic M; Praprotnik S; Dolzan V
Pharmacogenomics J; 2017 Oct; 17(5):412-418. PubMed ID: 27217051
[TBL] [Abstract][Full Text] [Related]
20. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]